Basic universal healthcare, the growth of medical tourism, and foreign investment incentives schemes introduced by the Thai Board of Investment (BOI) have each contributed to the growth of Thailand’s healthcare and pharmaceutical sectors.
However, if not regulatory-ready, healthcare and pharmaceutical companies entering the Thai market may encounter regulatory and compliance challenges as the industry is regulated by a broad framework of legislation and regulations. As healthcare and pharmaceutical companies constantly innovate and evolve, regulatory policymaking may also impact on their businesses.
Siam Premier understands the healthcare and pharmaceutical industry and makes sense of its complex legal framework. We assist global pharmaceutical companies implement their Thai market entry strategy, working closely with them to set up the right corporate structure and establish robust operations within the regulatory framework. We also advise pharmaceutical companies on matters affecting their day-to-day operations including in relation to R&D, clinical trials, manufacturing, employment and labour, environment, labelling, advertising, and sales of pharmaceuticals. And, when they are looking to invest or divest, our corporate / M&A team assists them to execute their domestic and cross-border M&A strategies.
We have experience in advising some of the world’s largest pharmaceutical companies on sensitive and complex regulatory matters in Thailand.
In the Healthcare sector, we advise hospital groups and clinics on corporate and regulatory matters affecting their operations, including in relation to licensing and permits.
Our expertise in the Healthcare and Pharmaceutical sectors includes advising on:
- BOI tax and non-tax incentive schemes
- Hospital licenses
- Intellectual Property (IP) enforcement and litigation
- Market entry and exit
- Mergers & Acquisitions
- Regulatory and compliance matters
- Thai Food and Drug Administration (TFDA) registration and licenses
